Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MandA

- PMLiVE

FDA panel backs Sprout Pharma’s ‘female Viagra’

Could be approved for HSDD in pre-menopausal women

- PMLiVE

FDA approves two new IBS medicines

US regulator gives the nod to Actavis’ and Salix’ bowel drugs

- PMLiVE

Valeant raises offer for Salix; rival Endo bows out

Has increased bid to $173 per share in cash

- PMLiVE

Endo tries to ride out Valeant with $15.7bn bid for Salix

Around $1.2bn more than rival bid

- PMLiVE

Valeant swoops on Salix with $10bn takeover deal

Firm will also absorb Salix’s $4.6bn debt, adding to its existing $15bn

- PMLiVE

Valeant and Shire said to be evaluating potential Salix bids

Valeant currently in final stages of Provenge acquisition

- PMLiVE

Valeant lead bidder for troubled Dendreon

Willing to pay $296m for company behind prostate cancer vaccine Provenge

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

- PMLiVE

Allergan ‘close’ to $60bn takeover agreement with Actavis

If successful the negotiations would scupper Valeant's hostile bid

- PMLiVE

Actavis ‘considering’ white knight bid for Allergan

Wall Street Journal says Irish pharma company set to challenge Valeant's bid

- PMLiVE

Valeant dangles higher bid in front of Allergan shareholders

Proposes $200 a share deal

- PMLiVE

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links